Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted into dopamine, restoring deficient neurotransmission. Benserazide inhibits peripheral aromatic L‑amino acid decarboxylase, preventing levodopa’s premature conversion outside the brain, thereby enhancing central availability and reducing peripheral side effects.

The appropriate dose of Madopar is individualized by the prescribing clinician based on disease severity, patient response, and tolerability. Dosage regimens vary widely, and adjustments are made during treatment to achieve optimal symptom control while minimizing adverse effects.

The safety of Madopar in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made in consultation with a qualified healthcare professional.

To request Madopar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central levodopa availability than levodopa alone. Compared with dopamine agonists, it provides more potent symptom relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors and treatment goals.

Madopar tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Madopar is taken orally, usually with a glass of water. It may be administered with food to reduce gastrointestinal upset, but patients should follow the specific timing instructions provided by their prescriber to maintain consistent plasma levels.

Serious risks include the development of dyskinesia (involuntary movements), severe hypotension, psychiatric disturbances such as hallucinations, and rare allergic reactions. Patients should be monitored regularly for these events, and any concerning symptoms should prompt immediate medical evaluation.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, and in individuals taking non‑selective MAO inhibitors. Caution is also advised for patients with severe cardiovascular disease, narrow‑angle glaucoma, or a history of malignant neuroleptic syndrome.